Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Rockwell Medical, Inc. Short Interest Update - Insider Trading Report |
 |
 |
|
Rockwell Medical, Inc. (NASDAQ:RMTI), A rise of 53,977 shares or 0.5% was seen in the short interest of Rockwell Medical, Inc. Even as the interest increased from 11,430,065 shares on May 29,2015 to 11,484,042 shares on June 15,2015, the days to cover came in at 16. The updated interest stood at 24.4% of the stocks floats. The shares has an average daily volume of 736,707 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th. The company shares have shown gains of 26.08% in the past 52 Weeks. On June 16, 2015 The shares registered one year high of $15.04 and one year low was seen on December 15, 2014 at $8.1. The 50-day moving average is $11.47 and the 200 day moving average is recorded at $10.55. S&P 500 has rallied 8.87% during the last 52-weeks. Rockwell Medical, Inc. (NASDAQ:RMTI) : On Wednesday heightened volatility was witnessed in Rockwell Medical, Inc. (NASDAQ:RMTI) which led to swings in the share price. The shares opened for trading at $14.94 and hit $16.69 on the upside , eventually ending the session at $16.64, with a gain of 11.3% or 1.69 points. The heightened volatility saw the trading volume jump to 2,722,790 shares. The 52-week high of the share price is $15.04 and the company has a market cap of $835 million. The 52-week low of the share price is at $8.095 . Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol. |
